Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Abstract

We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR). Eighteen children with autistic disorder completed a 12-week double-blind, placebo-controlled, randomized crossover study of fluvoxamine. Behavioral assessments were obtained before and at 12 weeks of treatment. 5-HTTLPR (long (l) or short(s)), was analyzed by the PCR method. Ten out of 18 patients responded to fluvoxamine treatment; allele type analysis revealed that clinical global effectiveness was noted significantly more in the l allele than in the s allele. However, with respect to language use, a significant effectiveness was noted in the s allele. 5-HTTLPR may influence the individual responses to fluvoxamine administration.

• Authors: Yoko Sugie, Hideo Sugie, Tokiko Fukuda, Masataka Ito, Yumiko Sasada, Mutsumi Nakabayashi, Kazunobu Fukashiro, Takehiko Ohzeki
• Journal: Journal of autism and developmental disorders (J Autism Dev Disord) Vol. 35 Issue 3 Pg. 377-85 (Jun 2005) ISSN: 0162-3257 [Print] United States
• PMID: 16119478 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Serotonin Plasma Membrane Transport Proteins
• Serotonin Uptake Inhibitors
• Fluvoxamine

Topics

• Alleles
• Autistic Disorder (drug therapy, genetics)
• Child
• Child, Preschool
• Cross-Over Studies
• Double-Blind Method
• Fluvoxamine (therapeutic use)
• Gene Expression
• Genotype
• Humans
• Polymorphism, Genetic (genetics)
• Promoter Regions, Genetic (genetics)
• Serotonin Plasma Membrane Transport Proteins (genetics)
• Selective Serotonin Reuptake Inhibitors (therapeutic use)